{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:13:31Z","timestamp":1793186011776,"version":"4.5.0"},"reference-count":117,"publisher":"The Company of Biologists","issue":"5","license":[{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"vor","delay-in-days":858,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007155","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/M008525\/1"],"award-info":[{"award-number":["MR\/M008525\/1"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000319","name":"Alzheimer's Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish State Support for Clinical Research"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leonard Wolfson Experimental Neurology Centre","award":["MR\/M008525\/1"],"award-info":[{"award-number":["MR\/M008525\/1"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["BRC149\/NS\/MH"],"award-info":[{"award-number":["BRC149\/NS\/MH"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The neurodegenerative disorder Alzheimer's disease is characterised by the formation of \u03b2-amyloid plaques and neurofibrillary tangles in the brain parenchyma, which cause synapse and neuronal loss. This leads to clinical symptoms, such as progressive memory deficits. Clinically, these pathological changes can be detected in the cerebrospinal fluid and with brain imaging, although reliable blood tests for plaque and tangle pathologies remain to be developed. Plaques and tangles often co-exist with other brain pathologies, including aggregates of transactive response DNA-binding protein 43 and Lewy bodies, but the extent to which these contribute to the severity of Alzheimer's disease is currently unknown. In this \u2018At a glance\u2019 article and poster, we summarise the molecular biomarkers that are being developed to detect Alzheimer's disease and its related pathologies. We also highlight the biomarkers that are currently in clinical use and include a critical appraisal of the challenges associated with applying these biomarkers for diagnostic and prognostic purposes of Alzheimer's disease and related neurodegenerative disorders, also in their prodromal clinical phases.<\/jats:p>","DOI":"10.1242\/dmm.031781","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T08:20:10Z","timestamp":1525767610000},"source":"Crossref","is-referenced-by-count":176,"title":["Molecular biomarkers of Alzheimer's disease: progress and prospects"],"prefix":"10.1242","volume":"11","author":[{"given":"Tammaryn","family":"Lashley","sequence":"first","affiliation":[{"name":"Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Schott","sequence":"additional","affiliation":[{"name":"Dementia Research Centre, UCL Institute of Neurology, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Weston","sequence":"additional","affiliation":[{"name":"Dementia Research Centre, UCL Institute of Neurology, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina E.","family":"Murray","sequence":"additional","affiliation":[{"name":"Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henny","family":"Wellington","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK"},{"name":"UK Dementia Research Institute, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashvini","family":"Keshavan","sequence":"additional","affiliation":[{"name":"Dementia Research Centre, UCL Institute of Neurology, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine C.","family":"Foti","sequence":"additional","affiliation":[{"name":"Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Foiani","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK"},{"name":"UK Dementia Research Institute, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Toombs","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK"},{"name":"UK Dementia Research Institute, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Rohrer","sequence":"additional","affiliation":[{"name":"Dementia Research Centre, UCL Institute of Neurology, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK"},{"name":"UK Dementia Research Institute, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4671-6763","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK"},{"name":"UK Dementia Research Institute, London WC1N 3BG, UK"},{"name":"Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal S-431 80, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal S-431 80, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"2021042612354024000_DMM031781C1","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/mds.26668","article-title":"Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia","volume":"31","author":"Abdelnour","year":"2016","journal-title":"Mov. Disord."},{"key":"2021042612354024000_DMM031781C2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.dadm.2016.05.005","article-title":"Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders","volume":"3","author":"Andreasson","year":"2016","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"2021042612354024000_DMM031781C4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2021042612354024000_DMM031781C5","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jalz.2016.04.005","article-title":"Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia","volume":"12","author":"Bereczki","year":"2016","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"2021042612354024000_DMM031781C7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"2021042612354024000_DMM031781C8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","article-title":"Amyloid biomarkers in Alzheimer's disease","volume":"36","author":"Blennow","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"2021042612354024000_DMM031781C9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","article-title":"SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease","volume":"9","author":"Brinkmalm","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"2021042612354024000_DMM031781C10","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"key":"2021042612354024000_DMM031781C11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1212\/WNL.0000000000003094","article-title":"Predicting Alzheimer disease from a blood-based biomarker profile: a 54-month follow-up","volume":"87","author":"Burnham","year":"2016","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1212\/WNL.0000000000003050","article-title":"Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly","volume":"87","author":"Chhatwal","year":"2016","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","article-title":"Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo","volume":"48","author":"Cirrito","year":"2005","journal-title":"Neuron"},{"key":"2021042612354024000_DMM031781C14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1590\/S0004-282X2011000400009","article-title":"Chemokines in CSF of Alzheimer's disease patients","volume":"69","author":"Corr\u00eaa","year":"2011","journal-title":"Arq. Neuropsiquiatr."},{"key":"2021042612354024000_DMM031781C15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","article-title":"YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease","volume":"68","author":"Craig-Schapiro","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"2021042612354024000_DMM031781C16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/jnnp.2006.107326","article-title":"CSF neurofilament proteins in the differential diagnosis of dementia","volume":"78","author":"de Jong","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2021042612354024000_DMM031781C17","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","article-title":"C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease","volume":"11","author":"De Vos","year":"2015","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C18","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"key":"2021042612354024000_DMM031781C19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"2021042612354024000_DMM031781C20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/21678421.2014.905606","article-title":"Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases","volume":"15","author":"Feneberg","year":"2014","journal-title":"Amyotroph. Lateral Scler. Frontotemporal. Degener."},{"key":"2021042612354024000_DMM031781C21","doi-asserted-by":"publisher","first-page":"348ra96","DOI":"10.1126\/scitranslmed.aaf6667","article-title":"Imaging synaptic density in the living human brain","volume":"8","author":"Finnema","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"2021042612354024000_DMM031781C22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejphar.2009.06.042","article-title":"In vitro characterisation of BF227 binding to alpha-synuclein\/Lewy bodies","volume":"617","author":"Fodero-Tavoletti","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"2021042612354024000_DMM031781C23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archneur.63.4.538","article-title":"Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease","volume":"63","author":"Galimberti","year":"2006","journal-title":"Arch. Neurol."},{"key":"2021042612354024000_DMM031781C24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1212\/01.wnl.0000191324.08289.9d","article-title":"Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration","volume":"66","author":"Galimberti","year":"2006","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C25","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042612354024000_DMM031781C26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2021042612354024000_DMM031781C27","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"key":"2021042612354024000_DMM031781C28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/alzrt255","article-title":"Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease","volume":"6","author":"Hansson","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"2021042612354024000_DMM031781C29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-015-0161-y","article-title":"Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease","volume":"7","author":"Hellwig","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"2021042612354024000_DMM031781C30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jalz.2016.09.009","article-title":"Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment","volume":"13","author":"Herukka","year":"2017","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","article-title":"Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease","volume":"11","author":"Heslegrave","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"2021042612354024000_DMM031781C32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke","volume":"297","author":"Hesse","year":"2001","journal-title":"Neurosci. Lett."},{"key":"2021042612354024000_DMM031781C33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/brain\/awq008","article-title":"DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease","volume":"133","author":"Hong","year":"2010","journal-title":"Brain"},{"key":"2021042612354024000_DMM031781C34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C35","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","article-title":"Biomarker modeling of Alzheimer's disease","volume":"80","author":"Jack","year":"2013","journal-title":"Neuron"},{"key":"2021042612354024000_DMM031781C36","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1093\/brain\/aww224","article-title":"TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia","volume":"139","author":"James","year":"2016","journal-title":"Brain"},{"key":"2021042612354024000_DMM031781C37","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma beta-amyloid in Alzheimer's disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci. Rep."},{"key":"2021042612354024000_DMM031781C38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer's disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2021042612354024000_DMM031781C39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2183\/pjab.90.353","article-title":"Novel plasma biomarker surrogating cerebral amyloid deposition","volume":"90","author":"Kaneko","year":"2014","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"2021042612354024000_DMM031781C40","doi-asserted-by":"publisher","first-page":"e81654","DOI":"10.1371\/journal.pone.0081654","article-title":"The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease","volume":"8","author":"Kapaki","year":"2013","journal-title":"PLoS ONE"},{"key":"2021042612354024000_DMM031781C41","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","article-title":"Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease","volume":"72","author":"Kester","year":"2015","journal-title":"JAMA Neurol."},{"key":"2021042612354024000_DMM031781C42","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/brain\/awq091","article-title":"In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy","volume":"133","author":"Kikuchi","year":"2010","journal-title":"Brain"},{"key":"2021042612354024000_DMM031781C43","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"2021042612354024000_DMM031781C44","doi-asserted-by":"publisher","first-page":"a023721","DOI":"10.1101\/cshperspect.a023721","article-title":"Tau positron emission tomography imaging","volume":"9","author":"Kolb","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2021042612354024000_DMM031781C45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/ijms17020189","article-title":"Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine","volume":"17","author":"Kovacs","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"2021042612354024000_DMM031781C46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2016.05.014","article-title":"CSF Abeta1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation","volume":"467","author":"Kuhlmann","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"2021042612354024000_DMM031781C47","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","article-title":"Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease","volume":"11","author":"Kvartsberg","year":"2015","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","article-title":"Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls","volume":"7","author":"Kvartsberg","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"2021042612354024000_DMM031781C49","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00702-017-1731-x","article-title":"In vivo PET imaging of neuroinflammation in Alzheimer's disease","volume":"125","author":"Lagarde","year":"2017","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"2021042612354024000_DMM031781C50","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-2377-13-54","article-title":"Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia","volume":"13","author":"Landqvist Wald\u00f6","year":"2013","journal-title":"BMC Neurol."},{"key":"2021042612354024000_DMM031781C51","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00401-007-0336-0","article-title":"Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients","volume":"115","author":"Lashley","year":"2008","journal-title":"Acta Neuropathol."},{"key":"2021042612354024000_DMM031781C52","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/bpa.12190","article-title":"TREM2 protein expression changes correlate with Alzheimer's disease neurodegenerative pathologies in post-mortem temporal cortices","volume":"25","author":"Lue","year":"2015","journal-title":"Brain Pathol."},{"key":"2021042612354024000_DMM031781C53","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","article-title":"A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes","volume":"86","author":"Magdalinou","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2021042612354024000_DMM031781C54","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Marqui\u00e9","year":"2015","journal-title":"Ann. Neurol."},{"key":"2021042612354024000_DMM031781C55","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042612354024000_DMM031781C56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","article-title":"Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility","volume":"13","author":"Mattsson","year":"2011","journal-title":"Neuromolecular Med."},{"key":"2021042612354024000_DMM031781C57","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/jnnp-2015-311321","article-title":"Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2021042612354024000_DMM031781C58","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C59","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.15252\/emmm.201707809","article-title":"(18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease","volume":"9","author":"Mattsson","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"2021042612354024000_DMM031781C60","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2217\/bmm.10.90","article-title":"Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies","volume":"4","author":"Mollenhauer","year":"2010","journal-title":"Biomark. Med."},{"key":"2021042612354024000_DMM031781C61","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet Neurol."},{"key":"2021042612354024000_DMM031781C62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-1-4939-7704-8_13","article-title":"Amyloid PET imaging: standardization and integration with other Alzheimer's disease biomarkers","volume":"1750","author":"Morbelli","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"2021042612354024000_DMM031781C63","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"2021042612354024000_DMM031781C64","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1074\/mcp.M116.059915","article-title":"Alpha-, Beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer's and Creutzfeldt-Jakob disease but no alteration in synucleinopathies","volume":"15","author":"Oeckl","year":"2016","journal-title":"Mol. Cell. Proteomics"},{"key":"2021042612354024000_DMM031781C65","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","article-title":"Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?","volume":"450","author":"\u00d6hrfelt","year":"2009","journal-title":"Neurosci. Lett."},{"key":"2021042612354024000_DMM031781C66","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1177\/1352458515624558","article-title":"Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone","volume":"22","author":"\u00d6hrfelt","year":"2016","journal-title":"Mult. Scler."},{"key":"2021042612354024000_DMM031781C67","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JAD-2012-120787","article-title":"Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia","volume":"33","author":"Olsson","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"2021042612354024000_DMM031781C68","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"2021042612354024000_DMM031781C69","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"key":"2021042612354024000_DMM031781C70","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C71","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/WCO.0000000000000489","article-title":"New PET markers for the diagnosis of dementia","volume":"30","author":"Payoux","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"2021042612354024000_DMM031781C72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/QAD.0000000000001314","article-title":"Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection","volume":"31","author":"Peluso","year":"2017","journal-title":"AIDS"},{"key":"2021042612354024000_DMM031781C73","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","article-title":"Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status","volume":"131","author":"Piccio","year":"2016","journal-title":"Acta Neuropathol."},{"key":"2021042612354024000_DMM031781C74","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","article-title":"Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease","volume":"138","author":"Portelius","year":"2015","journal-title":"Brain"},{"key":"2021042612354024000_DMM031781C75","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1515\/CCLM.2005.210","article-title":"Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice","volume":"43","author":"Ramont","year":"2005","journal-title":"Clin. Chem. Lab. Med."},{"key":"2021042612354024000_DMM031781C76","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neuroimage.2017.03.057","article-title":"A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages","volume":"155","author":"Rathore","year":"2017","journal-title":"Neuroimage"},{"key":"2021042612354024000_DMM031781C77","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1523\/JNEUROSCI.10-12-03782.1990","article-title":"Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate","volume":"10","author":"Represa","year":"1990","journal-title":"J. Neurosci."},{"key":"2021042612354024000_DMM031781C78","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/sj.mp.4001220","article-title":"Phospho-tau\/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias","volume":"8","author":"Riemenschneider","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"2021042612354024000_DMM031781C79","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","article-title":"Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias","volume":"12","author":"Sander","year":"2016","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C80","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jalz.2014.09.004","article-title":"The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data","volume":"11","author":"Schmidt","year":"2015","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C81","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ana.21706","article-title":"The neuropathology of probable Alzheimer disease and mild cognitive impairment","volume":"66","author":"Schneider","year":"2009","journal-title":"Ann. Neurol."},{"key":"2021042612354024000_DMM031781C82","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of Tau deposition in the aging human brain","volume":"89","author":"Sch\u00f6ll","year":"2016","journal-title":"Neuron"},{"key":"2021042612354024000_DMM031781C83","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/practneurol-2012-000315","article-title":"Alzheimer's disease: mimics and chameleons","volume":"12","author":"Schott","year":"2012","journal-title":"Pract. Neurol."},{"key":"2021042612354024000_DMM031781C84","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","article-title":"Alzheimer's disease is a synaptic failure","volume":"298","author":"Selkoe","year":"2002","journal-title":"Science"},{"key":"2021042612354024000_DMM031781C85","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1212\/WNL.0b013e3182563bd0","article-title":"CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings","volume":"78","author":"Seppala","year":"2012","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C86","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of Parkinson disease by detection of alpha-Synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2016","journal-title":"JAMA Neurol."},{"key":"2021042612354024000_DMM031781C87","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jalz.2016.04.003","article-title":"CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease","volume":"12","author":"Shi","year":"2016","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C88","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jalz.2016.09.008","article-title":"Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia","volume":"13","author":"Simonsen","year":"2017","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C89","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1212\/WNL.54.10.1960","article-title":"Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD","volume":"54","author":"Sjogren","year":"2000","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C90","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","article-title":"CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival","volume":"83","author":"Skillback","year":"2014","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C91","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1016\/j.jalz.2013.10.004","article-title":"Increased CSF alpha-synuclein levels in Alzheimer's disease: correlation with tau levels","volume":"10","author":"Slaets","year":"2014","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C92","doi-asserted-by":"publisher","first-page":"CD010632","DOI":"10.1002\/14651858.CD010632.pub2","article-title":"(1)(8)F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"1","author":"Smailagic","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"2021042612354024000_DMM031781C93","doi-asserted-by":"publisher","first-page":"38737","DOI":"10.1038\/srep38737","article-title":"Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease","volume":"6","author":"Steinacker","year":"2016","journal-title":"Sci. Rep."},{"key":"2021042612354024000_DMM031781C94","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are biomarkers?","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2021042612354024000_DMM031781C95","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","article-title":"sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers","volume":"8","author":"Su\u00e1rez-Calvet","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"2021042612354024000_DMM031781C96","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1084\/jem.20041611","article-title":"Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2","volume":"201","author":"Takahashi","year":"2005","journal-title":"J. Exp. Med."},{"key":"2021042612354024000_DMM031781C97","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","article-title":"Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease","volume":"73","author":"Tarawneh","year":"2016","journal-title":"JAMA Neurol."},{"key":"2021042612354024000_DMM031781C98","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/WAD.0b013e31823899cc","article-title":"Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease","volume":"26","author":"Tateno","year":"2012","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"2021042612354024000_DMM031781C99","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","article-title":"Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease","volume":"1362","author":"Thorsell","year":"2010","journal-title":"Brain Res."},{"key":"2021042612354024000_DMM031781C100","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C101","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-015-1485-1","article-title":"Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies","volume":"131","author":"Uchihara","year":"2016","journal-title":"Acta Neuropathol."},{"key":"2021042612354024000_DMM031781C102","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3233\/JAD-2010-090649","article-title":"CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease","volume":"21","author":"van Eijk","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"2021042612354024000_DMM031781C103","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3233\/JAD-150020","article-title":"Blood protein markers of neocortical amyloid-beta burden: a candidate study using SOMAscan technology","volume":"46","author":"Voyle","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"2021042612354024000_DMM031781C104","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev-neuro-071714-033828","article-title":"Neurodegenerative diseases: expanding the prion concept","volume":"38","author":"Walker","year":"2015","journal-title":"Annu. Rev. Neurosci."},{"key":"2021042612354024000_DMM031781C105","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.0b013e3181dd4dd8","article-title":"CSF biomarkers predict a more malignant outcome in Alzheimer disease","volume":"74","author":"Wallin","year":"2010","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C106","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1212\/WNL.0b013e318247caa1","article-title":"Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease","volume":"78","author":"Watabe-Rudolph","year":"2012","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C107","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","article-title":"Increased CSF neurogranin concentration is specific to Alzheimer disease","volume":"86","author":"Wellington","year":"2016","journal-title":"Neurology"},{"key":"2021042612354024000_DMM031781C108","doi-asserted-by":"publisher","first-page":"e53250","DOI":"10.1371\/journal.pone.0053250","article-title":"Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy","volume":"8","author":"Wennstr\u00f6m","year":"2013","journal-title":"PLoS ONE"},{"key":"2021042612354024000_DMM031781C109","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3233\/JAD-151155","article-title":"Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly","volume":"52","author":"Westwood","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"2021042612354024000_DMM031781C110","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer's disease and other dementias: a priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol."},{"key":"2021042612354024000_DMM031781C111","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dadm.2016.04.001","article-title":"Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile","volume":"3","author":"Winston","year":"2016","journal-title":"Alzheimers Dement."},{"key":"2021042612354024000_DMM031781C112","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1002\/jnr.22081","article-title":"Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions","volume":"87","author":"Yin","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"2021042612354024000_DMM031781C113","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/j.neurobiolaging.2015.07.021","article-title":"Plasma amyloid beta-quo vadis?","volume":"36","author":"Zetterberg","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"2021042612354024000_DMM031781C114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2016.06.030","article-title":"Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration","volume":"91","author":"Zetterberg","year":"2016","journal-title":"Neuron"},{"key":"2021042612354024000_DMM031781C115","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/nan.12378","article-title":"Review: Tau in biofluids - relation to pathology, imaging and clinical features","volume":"43","author":"Zetterberg","year":"2017","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"2021042612354024000_DMM031781C116","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer's disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res. Ther."},{"key":"2021042612354024000_DMM031781C117","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol."}],"container-title":["Disease Models &amp; Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1242\/dmm.031781","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.031781\/1862295\/dmm031781.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.031781\/1862295\/dmm031781.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T14:15:55Z","timestamp":1619446555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dmm\/article\/11\/5\/dmm031781\/53195\/Molecular-biomarkers-of-Alzheimer-s-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":117,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.1242\/dmm.031781","relation":{},"ISSN":["1754-8411","1754-8403"],"issn-type":[{"value":"1754-8411","type":"electronic"},{"value":"1754-8403","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5,1]]},"article-number":"dmm031781"}}